Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 4,500 shares at $164.68 ($732K) on 2018-10-04, disclosed to the SEC on 2018-10-05.
Open-market sale of $732k LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $160.62 | 600 | $96K | 13.2% |
| 2 | $161.52 | 1,100 | $178K | 24.3% |
| 3 | $162.70 | 1,194 | $194K | 26.5% |
| 4 | $163.78 | 1,006 | $165K | 22.5% |
| 5 | $164.68 | 600 | $99K | 13.5% |
| Total | $162.64 avg | 4,500 |
| $732K |
| 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $426K | — | Filing → |
| LOXO | SELL | 2018-12-12 | $120K | — | Filing → |
| LOXO | SELL | 2018-11-28 | $1.5M | — | Filing → |